2003049236

10 SEP 2003

162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 2002/075318 A3

(51) International Patent Classification[7]: G01N 33/68, C07D 277/62, G01N 33/58, C07D 279/18

(21) International Application Number: PCT/GB2002/001318

(22) International Filing Date: 20 March 2002 (20.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0106953.3 20 March 2001 (20.03.2001) GB

(71) Applicant *(for all designated States except US)*: **THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN** [GB/GB]; Regent Walk, Aberdeen, Aberdeenshire AB24 3FX (GB).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **WISCHIK, Claude, Michel** [FR/GB]; Department of Mental Health, University of Aberdeen, University Medical Buildings, Foresterhill, Aberdeenshire AB25 2ZD (GB). **HARRINGTON, Charles, Robert** [GB/GB]; Department of Mental Health, University of Aberdeen, University Medical Buildings, Foresterhill, Aberdeenshire AB25 2ZD (GB). **RICKARD, Janet, Elizabeth** [GB/GB]; Department of Mental Health, University of Aberdeen, University Medical Buildings, Foresterhill, Aberdeenshire AB25 2ZD (GB). **HORSLEY, David** [GB/GB]; Department of Mental Health, University of Aberdeen, University Medical Buildings, Foresterhill, Aberdeenshire AB25 2ZD (GB).

(74) Agents: **KREMER, Simon, M.** et al.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

[Continued on next page]

(54) Title: NEUROFIBRILLARY LABELS



(57) Abstract: Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, which methods comprise the steps of: (i) introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and/or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines. Novel ligands (e.g. sulphonated-benzothiazole-like compounds) are also provided. The method may also include the use of "blocking ligands" to block competing binding sites. In other aspects the invention provides in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors.

WO 2002/075318 A3

ACTION